Phio Pharmaceuticals (PHIO)
NASDAQ:PHIO
Top Page
Phio Pharmaceuticals
(NASDAQ:PHIO)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.50
▲(26.05% Upside)
Action:ReiteratedDate:03/30/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn) and limited valuation support (negative P/E, no dividend). Offsetting these are improved capitalization with zero debt, moderately improving near-term technical momentum, and positive pipeline/manufacturing corporate updates that strengthen the development outlook.
Positive Factors
INTASYL RNAi platform
Phio's INTASYL self-delivering RNAi platform represents a durable technical moat: it enables targeted modulation of immune cells in the tumor microenvironment without complex delivery vectors. That platform-level capability supports multiple programs, underpins long-term pipeline optionality, and can create differentiation vs. incumbents.
Negative Factors
No revenue; persistent net losses
Phio remains a pre-commercial biotech with no revenue and sustained net losses, meaning intrinsic profitability is distant. Over the medium term this limits internal financing capacity, extends reliance on external capital, and raises execution risk if development timelines slip or trial outcomes vary from initial readouts.
Read all positive and negative factors
Positive Factors
Negative Factors
INTASYL RNAi platform
Phio's INTASYL self-delivering RNAi platform represents a durable technical moat: it enables targeted modulation of immune cells in the tumor microenvironment without complex delivery vectors. That platform-level capability supports multiple programs, underpins long-term pipeline optionality, and can create differentiation vs. incumbents.
Read all positive factors
Phio Pharmaceuticals (PHIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.41M
Dividend YieldN/A
Average Volume (3M)137.46K
Price to Earnings (P/E)―
Beta (1Y)2.49
Revenue GrowthN/A
EPS Growth83.95%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.15
Shares Outstanding11,617,250
10 Day Avg. Volume82,534
30 Day Avg. Volume137,459
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.79
Enterprise Value/Market Cap-0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.15
Enterprise Value/Ebitda0.74
Forecast
1Y Price Target
$14.00Price Target Upside1076.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1
Revenue Forecast (FY)N/A
Phio Pharmaceuticals Business Overview & Revenue Model
Company Description
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that ac...
How the Company Makes Money
null...
Phio Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.00K | -3.64M | -6.33M | -7.01M | -8.89M |
| EBITDA | -9.22M | -7.38M | -10.64M | -11.39M | -13.44M |
| Net Income | -8.70M | -7.15M | -10.83M | -11.48M | -13.29M |
Balance Sheet | |||||
| Total Assets | 21.49M | 5.74M | 9.36M | 12.81M | 25.17M |
| Cash, Cash Equivalents and Short-Term Investments | 21.03M | 5.38M | 8.49M | 11.78M | 24.06M |
| Total Debt | 0.00 | 0.00 | 35.00K | 170.00K | 295.00K |
| Total Liabilities | 1.34M | 1.01M | 1.63M | 1.97M | 3.24M |
| Stockholders Equity | 20.15M | 4.72M | 7.73M | 10.84M | 21.93M |
Cash Flow | |||||
| Free Cash Flow | -7.99M | -7.11M | -10.75M | -12.25M | -11.91M |
| Operating Cash Flow | -7.98M | -7.11M | -10.75M | -12.13M | -11.86M |
| Investing Cash Flow | -12.00K | 8.00K | -5.00K | -121.00K | -51.00K |
| Financing Cash Flow | 23.64M | 4.00M | 7.41M | -26.00K | 21.72M |
Phio Pharmaceuticals Technical Analysis
Positive
1.19
Price Trends
1.15
Positive
1.17
Positive
1.70
Negative
Market Momentum
0.03
Negative
54.09
Neutral
61.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHIO, the sentiment is Positive. The current price of 1.19 is below the 20-day moving average (MA) of 1.24, above the 50-day MA of 1.15, and below the 200-day MA of 1.70, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 54.09 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHIO.
Phio Pharmaceuticals Risk Analysis
Phio Pharmaceuticals disclosed 26 risk factors in its most recent earnings report. Phio Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Phio Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $14.41M | -1.29 | -107.58% | ― | ― | 83.95% | |
45 Neutral | $72.89M | -5.32 | -71.26% | ― | 185.71% | 79.03% | |
44 Neutral | $7.14M | -1.02 | 553.15% | ― | -29.78% | 88.96% | |
44 Neutral | $6.39M | -0.82 | -420.31% | ― | 1.70% | -111.67% | |
39 Underperform | $370.80K | ― | -1302.82% | ― | ― | 99.09% |
* Healthcare Sector Average
PHIO
Phio Pharmaceuticals
1.24
0.23
22.77%
IBIO
Ibio
2.11
0.91
75.83%
EVGN
Evogene
0.82
-0.23
-22.00%
WINT
Windtree Therapeutics
0.01
-1.29
-99.15%
BRTX
BioRestorative Therapies
0.25
-1.51
-85.80%
LIXT
Lixte Biotechnology Holdings
2.85
1.75
159.09%
Phio Pharmaceuticals Corporate Events
Business Operations and Strategy
Phio Pharmaceuticals Secures cGMP Manufacturing for Clinical Supply
Positive
Mar 30, 2026
On March 30, 2026, Phio Pharmaceuticals announced it had signed a cGMP drug product manufacturing services agreement with a U.S. manufacturer to secure clinical supply. The move underscores the company’s efforts to advance its pipeline into,...
Executive/Board Changes
Phio Pharmaceuticals Boosts CEO Severance and Incentive Compensation
Neutral
Feb 18, 2026
On February 17, 2026, Phio Pharmaceuticals Corp. amended the employment agreement of its President and CEO, Robert J. Bitterman, revising key severance and incentive terms. The change increases his severance to 12 months of base salary if he is te...
Business Operations and StrategyProduct-Related Announcements
Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results
Positive
Feb 10, 2026
On February 10, 2026, Phio Pharmaceuticals reported that an independent Safety Monitoring Committee completed its review of the Phase 1b trial of PH-762 in skin cancers with a positive safety conclusion, finding no serious adverse events or dose-l...
Business Operations and StrategyProduct-Related Announcements
Phio Reports Positive Phase 1b PH-762 Skin Cancer Data
Positive
Jan 20, 2026
On January 20, 2026, Phio Pharmaceuticals reported pathology and safety data from all five cohorts in its Phase 1b intratumoral PH-762 dose-escalation trial in cutaneous carcinomas, showing favorable safety and tolerability across a 20-fold dose r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.